RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.
On June 6, 2017, Relmada Therapeutics, Inc. (the Company) and
Actinium Pharmaceuticals, Inc. (Actinium) entered into an
Assignment and Consent Agreement (the Assignment Agreement) to
which the Company transferred to Actinium, all of the Company’s
right, title and interest in and to Agreement of Lease with GP
275 Owner, LLC for a portion of the seventh floor located at 275
Madison Avenue, New York, New York, the former corporate
headquarters of the Company.
On June 6, 2017, the Company changed its corporate headquarters
to 750 Third Avenue, 9th Floor, New York, NY 10017
(the Premises). to a Lease Agreement, dated May 2, 2017 (the
Lease Agreement), between the Company and Regus Management Group,
LLC, the Company occupies a portion of the 9th Floor
at 750 Third Avenue, New York, NY 10017. The monthly rental fee
for the Premises is $8,294 per month. The Lease Agreement expires
on January 31, 2018. A copy of the Lease Agreement will be
included as an exhibit to the Companys Form 10-K for the year
ending June 30, 2017.
On June 8, 2017, the Company also entered into an Amended and
Restated License Agreement (the License) with Actinium for office
space located at 275 Madison Avenue, 7thFloor, New
York, NY 10016. This agreement amends and restates the license
agreement entered into between the parties on March 10, 2016. to
the terms of the License, Actinium will continue to license the
furniture, fixtures, equipment and tenant improvements located in
the Premises (the FFE). Actinium will pay to the Company a
license fee of $7,529 per month. Actinium shall have at any time
during the term of this Agreement the right to purchase the FFE.
The term of the License is contemporaneous with the Lease. A copy
of the License will be included as an exhibit to the Companys
Form 10-K for the year ending June 30, 2017.
Item5.02.Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
Departure of Director
On June 6, 2017 (the Resignation Date), Sandesh Seth, director
and Chairman of the Board, resigned from the Company to focus his
attention on matters external to Relmada. There was no
disagreement on any matters relating to the Companys operations,
policies or practices. The Company also entered into an agreement
(the Agreement) with Mr. Seth. to the terms of the Agreement, the
Company agrees to continue its advisory and consulting
arrangement with Mr. Seth to the terms of the Advisory and
Consulting Agreement, dated August 4, 2015 until December 31,
2017. Each of Mr. Seths outstanding options to acquire Company
common stock shall be 100% vested upon the Resignation Date and
shall be exercisable until the end of the term of each option
grant agreement. The Agreement also contains customary
cooperation, release, and non-disparagement provisions. A copy of
the Agreement will be included as an exhibit to the Companys Form
10-K for the year ending June 30, 2017.
About RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD)
Relmada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to treat chronic pain. Its product candidates include d-Methadone (dextromethadone, REL-1017), LevoCap ER (REL-1015), BuTab (REL-1028) and MepiGel (REL-1021). Its d-Methadone is an N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain. Its REL-1015 is an extended release, abuse deterrent formulation of the opioid analgesic levorphanol, which is pharmacologically differentiated from morphine, oxycodone and other opioids for the management of pain severe enough to require daily, around-the-clock and long-term opioid treatment. REL-1028 represents formulations of oral, modified release buprenorphine being developed for both chronic pain and opioid dependence indications. REL-1021 is a topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies.